Cargando…

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study

BACKGROUND: Chronic kidney disease (CKD) is a risk factor for severe coronavirus disease 2019 (COVID-19). We aimed to evaluate the real-life effectiveness of the BNT162b2 messenger RNA vaccine for a range of outcomes in patients with CKD compared with matched controls. METHODS: Data from Israel'...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bielopolski, Dana, Libresco, Gilad, Barda, Noam, Dagan, Noa, Steinmetz, Tali, Yahav, Dafna, Charytan, David M, Balicer, Ran D, Rozen-Zvi, Benaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384353/ https://www.ncbi.nlm.nih.gov/pubmed/36147707 http://dx.doi.org/10.1093/ckj/sfac166

Ejemplares similares

Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
por: Dagan, Noa, et al.
Publicado: (2021)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study
por: Yelin, Dana, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
por: Yahav, Dafna, et al.
Publicado: (2022)

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
por: Auster, Oren, et al.
Publicado: (2022)

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
por: Barda, Noam, et al.
Publicado: (2021)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
por: Yahav, Dafna, et al.
Publicado: (2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Precautions after vaccinating immunosuppressed patients with mRNA-based vaccines against SARS-CoV-2: does one size fit all?
por: Tau, Noam, et al.
Publicado: (2021)

Microalbuminuria After Kidney Transplantation Predicts Cardiovascular Morbidity
por: Bielopolski, Dana, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
por: Rozen-Zvi, Benaya, et al.
Publicado: (2021)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
por: Herman-Edelstein, Michal, et al.
Publicado: (2022)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
por: Barda, Noam, et al.
Publicado: (2022)

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
por: Katz, Mark A., et al.
Publicado: (2022)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022)

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
por: Dagan, Noa, et al.
Publicado: (2022)

Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel
por: Waxman, Jacob G., et al.
Publicado: (2022)

MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population
por: Ben Shachar, Shay, et al.
Publicado: (2021)

The prognostic value of pre-operative coronary evaluation in kidney transplanted patients
por: Steinmetz, Tali, et al.
Publicado: (2022)

Change in Kidney Function and 2-Year Mortality After Transcatheter Aortic Valve Replacement
por: Witberg, Guy, et al.
Publicado: (2021)

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
por: Witberg, Guy, et al.
Publicado: (2021)

Indirect protection of children from SARS-CoV-2 infection through parental vaccination
por: Hayek, Samah, et al.
Publicado: (2022)

The Association Between Exposure to Low Magnesium Blood Levels After Renal Transplantation and Cardiovascular Morbidity and Mortality
por: Lahav, Itay, et al.
Publicado: (2021)

Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Association of opioid use disorder with healthcare utilization and cost in a public health system
por: Miron, Oren, et al.
Publicado: (2022)

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
por: Kustin, Talia, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
por: Hayek, Samah, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_99magvavch6po8c5at6sgj32g5